Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Iradimed (IRMD) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to 32.23%.

  • Iradimed's EBITDA Margin rose 6400.0% to 32.23% in Q3 2025 from the same period last year, while for Sep 2025 it was 30.87%, marking a year-over-year increase of 9600.0%. This contributed to the annual value of 29.99% for FY2024, which is 5700.0% down from last year.
  • Iradimed's EBITDA Margin amounted to 32.23% in Q3 2025, which was up 6400.0% from 33.26% recorded in Q2 2025.
  • In the past 5 years, Iradimed's EBITDA Margin ranged from a high of 35.78% in Q3 2023 and a low of 18.8% during Q2 2021
  • Over the past 5 years, Iradimed's median EBITDA Margin value was 29.57% (recorded in 2023), while the average stood at 28.68%.
  • In the last 5 years, Iradimed's EBITDA Margin soared by 619100bps in 2021 and then plummeted by -41900bps in 2024.
  • Over the past 5 years, Iradimed's EBITDA Margin (Quarter) stood at 26.19% in 2021, then increased by 9bps to 28.62% in 2022, then increased by 3bps to 29.57% in 2023, then grew by 1bps to 29.91% in 2024, then grew by 8bps to 32.23% in 2025.
  • Its last three reported values are 32.23% in Q3 2025, 33.26% for Q2 2025, and 27.84% during Q1 2025.